Form 8-K - Current report:
SEC Accession No. 0001558370-23-008389
Filing Date
2023-05-08
Accepted
2023-05-08 08:45:17
Documents
14
Period of Report
2023-05-05
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K apre-20230505x8k.htm   iXBRL 8-K 43086
2 EX-99.1 apre-20230505xex99d1.htm EX-99.1 9098
  Complete submission text file 0001558370-23-008389.txt   187122

Data Files

Seq Description Document Type Size
3 EX-101.SCH apre-20230505.xsd EX-101.SCH 3900
4 EX-101.DEF apre-20230505_def.xml EX-101.DEF 2845
5 EX-101.LAB apre-20230505_lab.xml EX-101.LAB 17246
6 EX-101.PRE apre-20230505_pre.xml EX-101.PRE 11356
8 EXTRACTED XBRL INSTANCE DOCUMENT apre-20230505x8k_htm.xml XML 4811
Mailing Address 3805 OLD EASTON ROAD DOYLESTOWN PA 18902
Business Address 3805 OLD EASTON ROAD DOYLESTOWN PA 18902 267-370-5219
Aprea Therapeutics, Inc. (Filer) CIK: 0001781983 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39069 | Film No.: 23895991
SIC: 2834 Pharmaceutical Preparations